Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New Mexico
Clinical trial register · United States · industry-sponsored

Clinical Trials in New Mexico, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9125 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 08 Oct 2026, 03:16 UTC
9125
Studies in scope
industry-sponsored, all four open statuses
4951
Recruiting now
open to new participants
2192
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4437 Illinois 2482 Georgia 2367 Arizona 2241
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca6 Zimmer Biomet4 GlaxoSmithKline4 Pfizer4 Janssen Research & Development, LLC3
State
California5301 Florida4437 Illinois2482 Georgia2367 Arizona2241
All 51 states
Target enrolment
to

Trials with a site in New Mexico

96 of 9125 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
NCT07850063Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
Boehringer Ingelheim
Phase 3
600
Arizona, California, Florida, Kansas, New Mexico, North Carolina
2026-10-23
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170Non-small Cell Lung Cancer
DrugsDivarasib·Opdivo·Nivolumab·Keytruda
Hoffmann-La Roche
Phase 3
400
California, Georgia, Michigan, Nevada, New Mexico
2026-09-30
Recruiting
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
NCT07489066Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
120
Alabama, California, Georgia, Illinois, Nebraska, New Mexico, Tennessee
2026-06-30
Recruiting
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
NCT07365319Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
DrugsEIK1001·Cisplatin/Carboplatin·Nab-paclitaxel·Pemetrexed
Eikon Therapeutics
Phase 2/3
750
Alabama, California, Colorado, Florida, Illinois, New Mexico, New York, Tennessee
2026-06-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311Multiple Myeloma
DrugsBelantamab mafodotin·Velcade·Carfilzomib·Pomalidomide
GlaxoSmithKline
Phase 2
200
California, Connecticut, Florida, Georgia, Louisiana, Maryland, Missouri, New Mexico
2026-04-15
Recruiting
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06842498Metastatic Castration-Resistant Prostate Cancer
Kyntra Bio
Phase 2
75
Arizona, California, Connecticut, Florida, Georgia, Louisiana, New Mexico, North Carolina
2026-02-22
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Arkansas, California, Florida, Georgia, Illinois, Indiana, New Mexico, North Carolina
2026-01-15
Recruiting
An External Control Arm Study in Non-Small Cell Lung Cancer
NCT07174388Non Small Cell Lung Cancer
N-Power Medicine
Observational
650
California, Delaware, Illinois, New Mexico, New York, Pennsylvania, Texas
2026-01-07
Recruiting
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
NCT07157033Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Pancreas Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma
Phase 1/2
36
California, Michigan, New Mexico, Texas
2026-01-01
Active, closed
Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)
NCT07109414Platinum-resistant Ovarian Cancer
DrugPrilukae
Novita Pharmaceuticals, Inc.
Phase 2/3
380
Arizona, Louisiana, New Mexico, Pennsylvania, Utah, Wisconsin
2025-12-29
Recruiting
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
NCT07333183Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
20
California, Florida, Illinois, Kansas, Massachusetts, Michigan, New Mexico, North Carolina
2025-12-23
Recruiting
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
NCT07062588Osteogenesis Imperfecta (OI)
DrugAGA2115
Angitia Incorporated Limited
Phase 2
80
Arizona, Connecticut, Delaware, Indiana, Missouri, New Mexico, Ohio, Oregon
2025-12-12
Recruiting
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
NCT07290036Psoriatic Arthritis, Axial Spondyloarthritis
UCB Biopharma SRL
Phase 1
392
Arizona, California, Colorado, Florida, Illinois, Michigan, New Jersey, New Mexico
2025-12-10
Recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
NCT07260877Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus)
Ventus Therapeutics U.S., Inc.
Phase 2
24
California, Florida, Indiana, Michigan, Missouri, New Mexico, New York, Tennessee
2025-12-03
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531Type 1 Diabetes
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
Recruiting
DESTINY-PANTUMOUR04
NCT07124000Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Observational
100
Alabama, Arizona, California, Colorado, Florida, Illinois, Kansas, New Mexico
2025-09-18
Recruiting
Evaluation of Potassium (K) and Ionized Calcium (iCa) Tests Using Capillary Specimens
NCT07287618Hematologic Tests
Abbott Point of Care
Not applicable
425
New Mexico, Pennsylvania, Wisconsin
2025-09-17
Recruiting
Clinical Evaluation of Precision for the Potassium and Ionized Calcium Tests in Capillary Specimens
NCT07287631Hematologic Tests
Abbott Point of Care
Not applicable
425
New Mexico, Pennsylvania, Wisconsin
2025-09-17
Recruiting
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT07029828Severe Alopecia Areata
DrugsRitlecitinib higher·Ritlecitinib lower
Pfizer
Phase 3
140
California, Florida, Indiana, Maryland, Michigan, Nebraska, New Mexico, New York
2025-09-10
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Alabama, California, Florida, Illinois, Louisiana, New Mexico, Ohio, South Carolina
2025-08-19
Recruiting
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT07196501Major Depressive Disorder
DrugNBI-1065845
Neurocrine Biosciences
Phase 3
550
California, Connecticut, Florida, Iowa, Louisiana, Missouri, New Mexico, New York
2025-08-18
Recruiting
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
NCT06624644Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
DrugsTemozolomide·Pembrolizumab
Linnaeus Therapeutics, Inc.
Phase 2/3
135
California, Colorado, Florida, Massachusetts, New Mexico, Pennsylvania
2025-08-06
Not yet open
Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
NCT06531031Bloodstream Infection, Sepsis, Septic Shock
Microbio Co Ltd
Observational
1,500
Indiana, Maryland, New Mexico, Tennessee, Texas
2025-08
Recruiting
Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
NCT06964685AMI Cardiogenic Shock
Abiomed Inc.
Observational
350
Arkansas, California, Florida, Hawaii, Illinois, Massachusetts, Michigan, New Mexico
2025-07-10
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
California, Colorado, Connecticut, Florida, Georgia, Louisiana, Mississippi, New Mexico
2025-06-13
Recruiting
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
NCT07028489Non Small Cell Lung Cancer
N-Power Medicine
Observational
130
California, Delaware, Idaho, Illinois, New Mexico, Pennsylvania, Texas
2025-06-05
Active, closed
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
NCT06925750Pulmonary Arterial Hypertension
DrugSotatercept
Merck Sharp & Dohme LLC
Phase 2
130
Colorado, Kansas, New Mexico
2025-05-12
Active, closed
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
NCT06928142Sjogren Disease
DrugSibeprenlimab
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
83
California, Florida, Illinois, Louisiana, Massachusetts, New Mexico, New York, North Carolina
2025-04-23
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Alabama, California, Florida, Minnesota, Missouri, New Mexico, Ohio, Oregon
2025-04-11
Recruiting
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
NCT06657144Metastatic Solid Tumor, Advanced Solid Tumor
DrugsCHS-114·Adrucil·Toripalimab·Cisplatin
Coherus Oncology, Inc.
Phase 1
154
Arizona, California, Colorado, Georgia, Louisiana, Michigan, Nevada, New Mexico
2025-04-01
Active, closed
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
NCT06726265Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
DrugsEfti·Pemetrexed·Keytruda·Paclitaxel
Immutep S.A.S.
Phase 3
756
Kentucky, New Mexico, Texas
2025-03-21
Active, closed
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048Neovascular Age-related Macular Degeneration (nAMD)
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Phase 4
274
California, Florida, Illinois, Massachusetts, Nevada, New Jersey, New Mexico, Tennessee
2025-03-14
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
NCT06646276Extensive-Stage Small Cell Lung Cancer
DrugsEtoposide·Atezolizumab·Nivolumab·Carboplatin
Bristol-Myers Squibb
Phase 3
530
Alabama, Arkansas, Florida, Georgia, Illinois, Minnesota, New Mexico, North Carolina
2025-02-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
750
Arizona, Arkansas, Florida, Illinois, Maryland, Massachusetts, Minnesota, New Mexico
2025-01-09
Recruiting
A Study of RSLV-132 in Females With Sjögren's Disease
NCT06440525Primary Sjögren Syndrome
Resolve Therapeutics
Phase 2
106
California, Florida, Illinois, Iowa, Massachusetts, New Mexico, North Carolina, Pennsylvania
2024-12-01
Active, closed
A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)
NCT06577935Postmenopausal Osteoporosis
Angitia Biopharmaceuticals
Phase 2
379
Alabama, Georgia, New Mexico, Pennsylvania, Washington
2024-10-31
Active, closed
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults
NCT06652100Acute Kidney Injury
BioPorto Diagnostics
Observational
800
Alabama, California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New Mexico
2024-10-28
Recruiting
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779Metastatic Castration-Resistant Prostate Cancer
DrugsMevrometostat·Xtandi·Enzalutamide
Pfizer
Phase 3
900
Arizona, Arkansas, California, Illinois, Nebraska, New Mexico, New York, South Carolina
2024-10-22
Not yet open
Preterm Infants Fed a Human Milk Fortifier
NCT05551975Growth
Abbott Nutrition
Not applicable
321
Arizona, Arkansas, Connecticut, Florida, Massachusetts, Missouri, New Mexico, New York
2024-09
Active, closed
Cancer Prevention for Young Rural Adults
NCT05618158Cancer
Klein Buendel, Inc.
Not applicable
1,796
Arizona, Colorado, New Mexico, Utah
2024-08-26
Recruiting
Nafamostat Efficacy in Phase 3 Registrational CRRT Study
NCT06150742Acute Kidney Injury
Talphera, Inc
Not applicable
70
California, Florida, Michigan, New Mexico, New York, Ohio, Pennsylvania, South Carolina
2024-08-15
Recruiting
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
NCT06459973Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Colorado, Connecticut, Florida, Kentucky, Missouri, Nevada, New Mexico, Oklahoma
2024-06-04
Active, closed
Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).
NCT06253923Traumatic Brain Injury
SHINKEI Therapeutics, Inc
Phase 2
45
California, Florida, Maine, Michigan, Missouri, New Jersey, New Mexico, North Carolina
2024-06-01
Recruiting
BostonGene and Exigent Genomic INsight Study
NCT06272864Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
BostonGene
Observational
400
Arkansas, California, Indiana, New Mexico, Oklahoma, Texas, Washington
2024-04-08
By invitation
Study to Collect Data for Neonatal Abstinence Syndrome (NAS) and Evaluate the Automated Data Collection Process
NCT06303986Neonatal Abstinence Syndrome
Rekovar Inc.
Observational
100
New Mexico
2024-03-18
Active, closed
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06402331Metastatic Castration-resistant Prostate Cancer
DrugFPI-2265
Fusion Pharmaceuticals Inc.
Phase 2
110
California, Florida, Iowa, Maryland, Michigan, Missouri, Nebraska, New Mexico
2024-03-05
Active, closed
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT05458674Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
DrugsTucatinib·Eribulin·Herceptin·Trastuzumab
Criterium, Inc.
Phase 2
17
Colorado, District of Columbia, New Mexico, Washington, Wisconsin
2024-01-30
Active, closed
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
394
California, Florida, Indiana, Louisiana, Maryland, Michigan, New Mexico, New York
2024-01-19
Active, closed
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916Diabetic Macular Edema (DME)
DrugsKHK4951·Aflibercept
Kyowa Kirin Co., Ltd.
Phase 2
150
Arizona, California, Colorado, Florida, Maryland, Nevada, New Jersey, New Mexico
2024-01-09
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
DrugsSotorasib·Pembrolizumab
Amgen
Phase 3
750
California, Delaware, Florida, Illinois, Kentucky, Massachusetts, New Mexico, New York
2023-11-16
Recruiting
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
NCT06157177Sciatica Acute, Lumbar Spinal Stenosis
DrugMetaxalone
Primus Pharmaceuticals
Phase 4
50
Alabama, California, Florida, Georgia, Michigan, New Mexico, North Carolina, Ohio
2023-11-15
Active, closed
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
NCT06101134Melanoma
DrugsPhesgo·Relatlimab·Opdivo·Nivolumab
Bristol-Myers Squibb
Phase 2
100
Alaska, Arizona, California, Georgia, Kentucky, New Mexico, Washington
2023-11-06
Active, closed
Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression
NCT06117501Recurrent Cubital Tunnel Syndrome, Recalcitrant Cubital Tunnel Syndrome
Axogen Corporation
Not applicable
20
Florida, Georgia, Indiana, New Mexico, Ohio, Pennsylvania, Utah
2023-10-19
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
106
California, Colorado, Florida, Georgia, Massachusetts, Minnesota, Missouri, New Mexico
2023-10-02
Active, closed
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
NCT06041269Rheumatoid Arthritis
DrugRosnilimab
AnaptysBio, Inc.
Phase 2
420
Arizona, California, Florida, Illinois, Louisiana, Massachusetts, New Mexico, North Carolina
2023-08-31
Active, closed
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
NCT05787821Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis
Zimmer Biomet
Observational
760
Colorado, Florida, Georgia, Kentucky, Michigan, Minnesota, Mississippi, New Mexico
2023-06-28
Active, closed
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
NCT05966480SLE
DrugEnvudeucitinib
Alumis Inc
Phase 2
408
Alabama, California, Florida, Georgia, Missouri, Nevada, New Jersey, New Mexico
2023-06-26
Active, closed
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
NCT05729568HIV-1 Infection
DrugsTeropavimab·Zinlirvimab·Lenacapavir
Gilead Sciences
Phase 2
83
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Missouri, New Mexico
2023-05-15
Active, closed
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
NCT05557591Advanced Non-Small Cell Lung Cancer
DrugsBNT116·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
51
California, Kentucky, New Mexico, New York, North Carolina, Texas, Virginia, Washington
2023-04-21
Active, closed
A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer
NCT05723562Neoplasms, Rectal
DrugDostarlimab
GlaxoSmithKline
Phase 2
154
California, New Mexico, New York, Pennsylvania, Tennessee, Texas, Virginia
2023-04-03
Active, closed
Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application
NCT05094089Hernia, Ventral, Hernia Incisional, Hernia Incisional Ventral
W.L.Gore & Associates
Observational
320
Georgia, Massachusetts, Michigan, New Mexico, New York, North Carolina, South Carolina, Virginia
2023-02-24
Active, closed
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378Lung Cancer, Non-Small Cell
DrugsNelistotug·Belrestotug·Dostarlimab·Pembrolizumab
GlaxoSmithKline
Phase 2
351
Florida, New Mexico, Tennessee, West Virginia
2022-10-14
Recruiting
International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder
NCT05590715Autism Spectrum Disorder
Stalicla SA
Observational
1,500
Arizona, California, Florida, Illinois, Missouri, New Mexico, Texas, Utah
2022-10-13
Active, closed
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma
NCT05323253Recurrent Squamous Cell Carcinoma
Alpha Tau Medical LTD.
Not applicable
86
Arizona, California, Florida, Georgia, Minnesota, New Jersey, New Mexico, New York
2022-09-21
Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd
AstraZeneca
Phase 2
454
California, Indiana, Kansas, Massachusetts, Michigan, New Jersey, New Mexico, New York
2022-09-06
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
506
California, Florida, Georgia, Illinois, Kansas, Massachusetts, New Mexico, New York
2022-08-04
Recruiting
A Prospective Registry to Enable Collection of Standardized Routine Care Oncology Patient Data
NCT06877884Cancer
N-Power Medicine
Observational
20,000
California, Delaware, Illinois, New Mexico, Pennsylvania, Texas
2022-08-01
Recruiting
A Study of YL201 in Patients With Advanced Solid Tumors
NCT05434234Advanced Solid Tumor
DrugTam-Peli
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
312
California, Colorado, District of Columbia, Massachusetts, Michigan, Missouri, New Mexico, New York
2022-05-25
Active, closed
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
NCT05301842Hepatocellular Carcinoma
DrugsTremelimumab·Lenvatinib·Durvalumab
AstraZeneca
Phase 3
760
Alabama, Arizona, California, Georgia, Maryland, New Mexico, New York, Tennessee
2022-03-28
Active, closed
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
NCT04770870Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
DT MedTech, LLC
Not applicable
94
Arkansas, California, Florida, Indiana, Maryland, New Mexico, North Carolina, Oklahoma
2022-02-01
By invitation
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
NCT05210803Neovascular Age-Related Macular Degeneration (nAMD)
DrugsLucentis·Ranibizumab
AbbVie
Phase 2
116
Arizona, California, Georgia, Maryland, Massachusetts, Minnesota, Nevada, New Mexico
2021-12-20
Recruiting
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
NCT04892173Carcinoma, Squamous Cell
DrugsJNJ-90301900·Erbitux·Cetuximab
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Alabama, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts, New Mexico
2021-12-10
Active, closed
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
NCT05039840Systemic Lupus Erythematosus
DrugFrexalimab
Sanofi
Phase 2
109
Alabama, Arizona, California, Florida, New Mexico, New York, Oklahoma, Tennessee
2021-11-10
Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer
DrugsPalacaparib·Saruparib·Rilvegostomig
AstraZeneca
Phase 1/2
460
California, Louisiana, Maryland, Massachusetts, Missouri, New Mexico, New York, North Carolina
2021-10-18
Active, closed
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755Neoplasms, Breast
DrugNiraparib
GlaxoSmithKline
Phase 3
40
California, Colorado, Illinois, Michigan, New Mexico, New York, North Dakota, Pennsylvania
2021-06-28
Recruiting
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
DrugsDPX-Survivac·Procytox·Cytoxan·Keytruda
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2
102
California, Florida, Georgia, Indiana, Louisiana, Nebraska, New Mexico, North Carolina
2021-06-18
Active, closed
Persona Ti-Nidium Post-Market Clinical Follow-up
NCT04817969Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis
Zimmer Biomet
Not applicable
240
Colorado, Maryland, Mississippi, New Mexico, North Carolina, Pennsylvania, South Dakota
2021-06-01
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
NCT04811560Acute Leukemia
DrugBleximenib
Janssen Research & Development, LLC
Phase 1/2
420
California, Illinois, Indiana, Kentucky, Massachusetts, Michigan, New Mexico, New York
2021-05-19
Active, closed
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT04567420Breast Cancer
DrugsPalbociclib·Fulvestrant
Criterium, Inc.
Phase 2
70
Arizona, California, Colorado, Connecticut, Georgia, Louisiana, Nebraska, New Mexico
2021-02-09
Active, closed
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
DrugPembrolizumab
BioNTech SE
Phase 2/3
358
California, Connecticut, District of Columbia, Florida, Georgia, Kentucky, Massachusetts, New Mexico
2021-01-07
Active, closed
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
NCT04430738Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma
DrugsTucatinib·Fluorouracil·Leucovorin·Trastuzumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
40
Arizona, Colorado, District of Columbia, Missouri, New Mexico, North Carolina, Ohio, Washington
2020-09-15
Active, closed
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)
NCT04526691Advanced or Metastatic NSCLC
DrugsDato-DXd·Keytruda·Cisplatin·Carboplatin
Daiichi Sankyo
Phase 1
145
Arizona, California, District of Columbia, Florida, Maryland, Minnesota, New Mexico, Texas
2020-09-15
Active, closed
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT04514653Neovascular Age-Related Macular Degeneration (nAMD)
DrugRanibizumab
AbbVie
Phase 2
146
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Nevada, New Mexico
2020-08-25
Active, closed
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
NCT04157348Eosinophilic Granulomatous Vasculitis
DrugsBenralizumab·Mepolizumab
AstraZeneca
Phase 3
140
Colorado, Michigan, Minnesota, New Mexico, New York, Pennsylvania, Texas, Washington
2019-10-29
Active, closed
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
NCT04130516Solid Tumor, Adult
DrugsKeytruda·Pembrolizumab
Linnaeus Therapeutics, Inc.
Phase 1/2
200
California, Connecticut, Massachusetts, New Mexico, New York, Pennsylvania, Texas
2019-10-21
Recruiting
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
NCT04064359Solid Tumor
Oxford BioTherapeutics Ltd
Phase 1
200
Arizona, California, Florida, Iowa, Kentucky, Mississippi, New Mexico, New York
2019-07-25
Active, closed
Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence
NCT03104517Stress Urinary Incontinence
DrugIltamiocel
Cook MyoSite
Phase 3
96
Arizona, California, District of Columbia, Kansas, Michigan, New Mexico, New York, North Carolina
2019-04-23
Recruiting
Clinical Pre-screening Protocol for Ovarian Cancer
NCT03877796Ovarian Cancer
Allarity Therapeutics
Observational
60
Florida, Georgia, New Mexico, New York, Oklahoma, Texas, Washington
2019-04-11
Active, closed
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
NCT03589339Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver
DrugsJNJ-90301900·Opdivo·Nivolumab·Keytruda
Nanobiotix
Phase 1
145
California, Florida, Georgia, Illinois, Maryland, Michigan, New Mexico, New York
2019-01-16
Active, closed
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
NCT03836352Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
DrugsCyclophosphamide·Pembrolizumab
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2
184
Arizona, California, Florida, Georgia, Kentucky, Louisiana, Minnesota, New Mexico
2018-12-21
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
California, Kansas, Louisiana, New Mexico, New York, South Carolina, Texas, Utah
2018-11-28
Recruiting
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
VM Oncology, LLC
Phase 1/2
242
California, Connecticut, District of Columbia, Florida, New Jersey, New Mexico, New York, Ohio
2018-06-08
Recruiting
Collection of Sputum and Labeling for Lung Cancer
NCT03457415Lung Cancer
bioAffinity Technologies Inc.
Observational
500
New Jersey, New Mexico, Texas
2018-03-01
Active, closed
Prospective G7 Dual Mobility Total Hip PMCF
NCT03308929Clinical Outcomes, Functional Outcomes, Radiological Outcomes, Survivorship
Zimmer Biomet
Observational
250
New Jersey, New Mexico, North Carolina, Oregon, Virginia
2017-02-28
Active, closed
Persona Partial Knee Clinical Outcomes Study
NCT03034811Osteoarthritis, Avascular Necrosis, Traumatic Arthritis, Conditional Tibial Condyle or Plateau Fractures
Zimmer Biomet
Not applicable
757
California, Colorado, Illinois, Indiana, Massachusetts, Michigan, New Mexico, South Carolina
2017-02-08
Active, closed
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02542293Non Small Cell Lung Carcinoma NSCLC
DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine
AstraZeneca
Phase 3
953
California, Kentucky, New Jersey, New Mexico, New York, Ohio, Pennsylvania, Texas
2015-11-03
Rows per page Showing 1–96 of 96
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 October 2026. https://priyalifescience.com/clinical-trials-usa/state/new-mexico

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,125 studies in total at the last sync on 08 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 96 of those studies with a site in New Mexico.

How many clinical trials are recruiting in New Mexico?

47 of the 96 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:16 UTC sync. A further 3 have not yet opened recruitment, 44 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (New Mexico), 96 studies
PhaseStudiesRecruitingShare
Phase 2331334.4%
Phase 3201020.8%
Observational15915.6%
Not applicable10310.4%
Phase 1/2767.3%
Phase 1535.2%
Phase 2/3424.2%
Phase 4212.1%

Most active sponsors

Lead sponsors with the most studies (New Mexico)
Lead sponsorStudiesRecruiting
AstraZeneca63
GlaxoSmithKline41
Pfizer43
Zimmer Biomet40
Janssen Research & Development, LLC33
N-Power Medicine33
Abbott Point of Care22
AbbVie20
Astellas Pharma Global Development, Inc.21
Bristol-Myers Squibb21
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.